Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors - PubMed (original) (raw)
. 1998 May 15;58(10):2095-7.
Affiliations
- PMID: 9605750
Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors
K Obata et al. Cancer Res. 1998.
Abstract
Epithelial ovarian cancer comprises three major histological subtypes (serous, mucinous, and endometrioid), and it is becoming clear that the developmental pathways for these subtypes are fundamentally different. In particular, endometrioid ovarian cancers probably arise by the malignant transformation of ectopic endometrial implants called endometriosis and not the ovarian surface epithelium. The PTEN/MMAC gene on chromosome 10q23 is a tumor suppressor implicated in the pathogenesis of a wide variety of malignancies, but to date, somatic mutations in PTEN have not been identified in studies of predominantly serous ovarian cancers. In endometrial cancers, PTEN mutations are very common in tumors of the endometrioid type but have rarely been found in serous types, and we hypothesized that a similar histological subtype bias might be occurring in ovarian cancer. We have analyzed 81 ovarian tumors, including 34 endometrioid, 29 serous, 10 mucinous, and 8 clear cell tumors, for loss of heterozygosity (LOH) on 10q23 and for mutations in all 9 coding exons of PTEN. LOH was common among the endometrioid (43%) and serous (28%) tumors but was infrequent among the other histological subtypes. Somatic PTEN mutations were detected in seven (21%) of the endometrioid tumors, and in all informative cases, the mutation was accompanied by loss of the wild-type allele. One mucinous tumor without 10q23 LOH was shown to harbor two somatic PTEN mutations. In this tumor, the histological appearance of the mucinous areas was atypical, and the mucinous areas contained foci of endometrioid differentiation. The majority of tumors with PTEN mutations were grade 1 and/or stage 1, suggesting that inactivation of PTEN is an early event in ovarian tumorigenesis. No PTEN mutations were found among the serous or clear cell tumors. The identification of frequent somatic PTEN mutations in endometrioid ovarian tumors indicates that it plays a significant role in the etiology of this subtype. The absence of mutations in other histological subtypes is consistent with the hypothesis that epithelial ovarian cancers arise through distinct developmental pathways.
Similar articles
- Common genetic changes between endometriosis and ovarian cancer.
Obata K, Hoshiai H. Obata K, et al. Gynecol Obstet Invest. 2000;50 Suppl 1:39-43. doi: 10.1159/000052877. Gynecol Obstet Invest. 2000. PMID: 11093060 Review. - [An approach to early genetic alterations in precancerous cells].
Sato N, Nishida M, Noguchi M. Sato N, et al. Hum Cell. 2000 Sep;13(3):103-8. Hum Cell. 2000. PMID: 11197771 Review. Japanese. - Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies.
Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, Li J, Parsons R, Ellenson LH. Tashiro H, et al. Cancer Res. 1997 Sep 15;57(18):3935-40. Cancer Res. 1997. PMID: 9307275 - Loss of heterozygosity and mutational analysis of the PTEN/MMAC1 gene in synchronous endometrial and ovarian carcinomas.
Lin WM, Forgacs E, Warshal DP, Yeh IT, Martin JS, Ashfaq R, Muller CY. Lin WM, et al. Clin Cancer Res. 1998 Nov;4(11):2577-83. Clin Cancer Res. 1998. PMID: 9829719
Cited by
- Impaired FHIT expression characterizes serous ovarian carcinoma.
Ozaki K, Enomoto T, Yoshino K, Fujita M, Buzard GS, Kawano K, Yamasaki M, Murata Y. Ozaki K, et al. Br J Cancer. 2001 Jul 20;85(2):247-54. doi: 10.1054/bjoc.2001.1886. Br J Cancer. 2001. PMID: 11461085 Free PMC article. - Expression profiling identifies genes involved in neoplastic transformation of serous ovarian cancer.
Merritt MA, Parsons PG, Newton TR, Martyn AC, Webb PM, Green AC, Papadimos DJ, Boyle GM. Merritt MA, et al. BMC Cancer. 2009 Oct 23;9:378. doi: 10.1186/1471-2407-9-378. BMC Cancer. 2009. PMID: 19849863 Free PMC article. - Establishment of an immortalised human ovarian surface epithelial cell line without chromosomal instability.
Maeda T, Tashiro H, Katabuchi H, Begum M, Ohtake H, Kiyono T, Okamura H. Maeda T, et al. Br J Cancer. 2005 Jul 11;93(1):116-23. doi: 10.1038/sj.bjc.6602662. Br J Cancer. 2005. PMID: 15956975 Free PMC article. - Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells.
Schlosshauer PW, Li W, Lin KT, Chan JL, Wang LH. Schlosshauer PW, et al. Gynecol Oncol. 2009 Sep;114(3):516-22. doi: 10.1016/j.ygyno.2009.06.002. Epub 2009 Jul 2. Gynecol Oncol. 2009. PMID: 19576622 Free PMC article. - Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy.
Bai H, Cao D, Yang J, Li M, Zhang Z, Shen K. Bai H, et al. J Cell Mol Med. 2016 Apr;20(4):581-93. doi: 10.1111/jcmm.12771. Epub 2016 Jan 22. J Cell Mol Med. 2016. PMID: 26800494 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials